FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback